艾塞那肽治疗肥胖2型糖尿病临床观察

目的探讨艾塞那肽治疗肥胖2型糖尿病患者的临床疗效及安全性。方法对56例血糖控制欠佳的肥胖2型糖尿病患者进行为期3个月的艾塞那肽治疗,分别于治疗前及治疗3个月后测定患者的空腹血糖、餐后2 h血糖、糖化血红蛋白、C肽、体质量,并观察不良反应。结果艾塞那肽治疗3个月后患者空腹血糖、餐后2 h血糖、糖化血红蛋白和体质量均显著下降(P<0.05),胰岛功能改善;不良反应可耐受。结论艾塞那肽有明显降低肥胖2型糖尿病患者空腹及餐后血糖、糖化血红蛋白及改善胰岛功能的作用,同时能够明显降低体质量,是治疗肥胖2型糖尿病有效且安全的降糖药物。

The clinical observation of Exenatide in treatment of obese patients with type 2 diabetes

Objective To investigate the clinical efficacy and safety of the Exenatide in treatment of obese patients with type 2 diabetes. Methods Fifty six patients with type 2 diabetes accepted three months of Exenatide treatment： The fasting blood glucose（FBG） ,blood glucose 2 hours post-prandial, hemoglobin Alc （HbAlc）, C-peptide, body weight changes and adverse reactions were measured before and after treatment. Results Three months after the Exenatide treatment, the FBG, blood glucose 2 hours post-prandial, HbAlc levels and body weight were significantly decreased（P〈0. 05）. The islet functions were improved ,and the adverse reactions could be tolerated. Conclusion The levels of functions is a kind fasting and post-prandial blood glucose, glycosylated hemoglobin were decreased and the islet were improved after the treatment of Exenatide in obese patients with type 2 diabetes. Exenatide of effective and safe anti-diabetic drug in treatment of obese patients with type 2 diabetes.